Earnings History Data for ARS Pharmaceuticals, Inc. (SPRY) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites. ARS Pharmaceuticals Inc., formerly known as Silverback Therapeutics Inc., is based in SEATTLE.

Release Date	Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
13-08-2026	AH	SPRY	ARS Pharmaceuticals, Inc.	590.85	-0.63	-0.55	-0.46	ARS Pharmaceuticals GAAP EPS of -$0.63 misses by $0.14, revenue of $33.7M beats by $2.38M [8/13/2026 4:30 PM]	5.67	-0.43 (-7.13%)	5.10	-1.00 (-16.39%)	4.91 - 15.72	4,725,873	1,810,000	44,359
ARS Pharmaceuticals GAAP EPS of -$0.63 misses by $0.14, revenue of $33.7M beats by $2.38M [8/13/2026 4:30 PM] ARS Pharmaceuticals drops on abandoning DTC neffy marketing, Q2 EPS miss [8/13/2026 4:59 PM] ARS Pharma targets cash flow breakeven by end of 2027 as it cuts cash-based SG&A and R&D to $100M-$110M in H2 2026 [8/14/2026 1:28 AM]
15-05-2026	PM	SPRY	ARS Pharmaceuticals, Inc.	795.40	-0.61	-0.53	-0.35	ARS Pharmaceuticals GAAP EPS of -$0.61 misses by $0.08, revenue of $22.68M beats by $0.56M [5/15/2026 6:12 AM]	7.42	-0.52 (-6.52%)	7.32	-0.62 (-7.81%)	6.66 - 18.90	2,772,093	1,830,000	640,001
ARS Pharmaceuticals Q1 2026 Earnings Preview [5/14/2026 12:11 PM] ARS Pharmaceuticals GAAP EPS of -$0.61 misses by $0.08, revenue of $22.68M beats by $0.56M [5/15/2026 6:12 AM]
09-03-2026	PM	SPRY	ARS Pharmaceuticals, Inc.	901.50	-0.42	-0.42	0.52	ARS Pharmaceuticals GAAP EPS of -$1.74 beats by $0.02, revenue of $84.28M beats by $2.6M [3/9/2026 6:04 AM]	9.11	0.05 (0.55%)	9.35	0.29 (3.20%)	6.66 - 18.90	1,449,086	930,000	10,550
ARS Pharmaceuticals GAAP EPS of -$1.74 beats by $0.02, revenue of $84.28M beats by $2.6M [3/9/2026 6:04 AM] ARS Pharmaceuticals outlines sales force expansion and digital strategy for neffy growth while maintaining SG&A in 2026 [3/9/2026 10:58 AM]
10-11-2025	PM	SPRY	ARS Pharmaceuticals, Inc.	809.88	-0.52	-0.45	-0.20	ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M [11/10/2025 6:05 AM]	8.88	0.03 (0.34%)	9.88	1.03 (11.64%)	8.05 - 18.90	3,631,437	1,790,000	82,715
ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M [11/10/2025 6:05 AM] ARS Pharmaceuticals targets renewed growth in 2026 as neffy adoption accelerates and new global launches begin [11/10/2025 2:02 PM]
13-08-2025	PM	SPRY	ARS Pharmaceuticals, Inc.	1,610	-0.46	-0.41	-0.13	ARS Pharmaceuticals GAAP EPS of -$0.46 beats by $0.01, revenue of $15.72M beats by $1.94M [8/13/2025 7:04 AM]	15.81	-0.85 (-5.10%)	16.25	-0.41 (-2.46%)	10.00 - 18.90	3,837,589	1,240,000	47,402
ARS Pharmaceuticals GAAP EPS of -$0.46 beats by $0.01, revenue of $15.72M beats by $1.94M [8/13/2025 7:04 AM] ARS Pharmaceuticals signals continued neffy momentum with 180% prescription surge and global expansion targets [8/13/2025 11:54 AM] Cisco Systems headlines earnings slate [2025-08-13 05:26AM] ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For [Aug-12-25 09:24AM]
14-05-2025	PM	SPRY	ARS Pharmaceuticals, Inc.	1,300	-0.35	-0.35	-0.11	ARS Pharmaceuticals GAAP EPS of -$0.35 in-line, revenue of $7.97M beats by $0.49M [5/14/2025 7:15 AM]	12.11	-1.24 (-9.33%)	12.55	-0.80 (-5.99%)	7.55 - 18.51	3,022,676	1,200,000	105,804
ARS Pharmaceuticals GAAP EPS of -$0.35 in-line, revenue of $7.97M beats by $0.49M [5/14/2025 7:15 AM] ARS Pharmaceuticals targets 80% commercial coverage for neffy in 2025 while expanding pediatric reach [5/14/2025 1:33 PM] ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy (epinephrine nasal spray) [2025-05-14 07:00AM] ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect [May-13-25 09:28AM]
20-03-2025	PM	SPRY	ARS Pharmaceuticals, Inc.	1,110	0.52	-0.10	-0.07	ARS Pharmaceuticals GAAP EPS of $0.08, revenue of $89.15M [3/20/2025 7:03 AM]	14.13	2.48 (21.33%)	12.15	0.50 (4.29%)	7.55 - 18.51	8,138,866	1,220,000	128,561
ARS Pharmaceuticals GAAP EPS of $0.08, revenue of $89.15M [3/20/2025 7:03 AM] ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion [3/20/2025 1:29 PM] ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates [2025-03-20 07:00AM]
13-11-2024	PM	SPRY	ARS Pharmaceuticals, Inc.	1,700	-0.20	-0.18	-0.16	ARS Pharmaceuticals GAAP EPS of -$0.20 misses by $0.05, revenue of $2.07M beats by $1.5M [11/13/2024 6:38 AM]	13.95	-2.66 (-16.01%)	16.00	-0.61 (-3.67%)	3.76 - 18.51	2,922,554	1,310,000	30,201
ARS Pharmaceuticals GAAP EPS of -$0.20 misses by $0.05, revenue of $2.07M [11/13/2024 6:38 AM] ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates [2024-11-13 06:30AM] ARS Pharmaceuticals announces agreement with ALK to commercialize neffy [Nov-12-24 07:06AM]
06-08-2024	AH	SPRY	ARS Pharmaceuticals, Inc.	959.00	-0.13	-0.12	0.00	ARS Pharmaceuticals GAAP EPS of -$0.13 misses by $0.02, revenue of $0.5M misses by $0.17M [8/6/2024 5:51 PM]	9.58	-0.20 (-2.06%)	9.78	0.0 (0.00%)	2.55 - 11.90	560,803	560,000	2,558
ARS Pharmaceuticals GAAP EPS of -$0.13 misses by $0.02, revenue of $0.5M misses by $0.17M [8/6/2024 5:51 PM]
09-05-2024	AH	SPRY	ARS Pharmaceuticals, Inc.	918.00	-0.11	-0.11	0.00	ARS Pharmaceuticals GAAP EPS of -$0.11 [5/9/2024 5:31 PM]	8.74	-0.06 (-0.68%)	9.14	0.34 (3.86%)	2.55 - 11.27	247,553	480,000	100
ARS Pharmaceuticals GAAP EPS of -$0.11 [5/9/2024 5:31 PM]
21-03-2024	AH	SPRY	ARS Pharmaceuticals, Inc.	812.00	-0.07	-0.14	0.00	ARS Pharmaceuticals reports Q4 results [3/21/2024 5:21 PM]	8.65	-0.35 (-3.83%)	8.99	-0.01 (-0.11%)	2.55 - 9.65	656,920	870,000	1,756
ARS Pharmaceuticals reports Q4 results [3/21/2024 5:21 PM]
10-08-2023	PM	SPRY	ARS Pharmaceuticals, Inc.	663.42	-0.18	-0.17	-0.55	ARS Pharmaceuticals GAAP EPS of -$0.18 beats by $0.03 [8/11/2023 9:58 AM]	6.82	-0.03 (-0.51%)	6.85	0.0 (0.00%)	3.99 - 9.65	470,610	290,000	9,767
ARS Pharmaceuticals GAAP EPS of -$0.18 beats by $0.03 [8/11/2023 9:58 AM]
15-05-2023	PM	SPRY	ARS Pharmaceuticals, Inc.	428.00	-0.16	-0.17	0.00	ARS Pharmaceuticals GAAP EPS of -$0.16 [5/15/2023 12:13 PM]	7.79	-0.25 (-3.11%)	0.0	0.0 (0.00%)	2.98 - 9.65	3,596,489	6,340,000	0
ARS Pharmaceuticals GAAP EPS of -$0.16 [5/15/2023 12:13 PM]